
RCEL Stock Forecast & Price Target
RCEL Analyst Ratings
Bulls say
AVITA Medical is a positive potential investment due to its innovative one-product RECELL system that speeds up the burn treatment process, leading to reduced healthcare costs and increased patient satisfaction. The recent contract with BARDA and expanding wound care portfolio also bode well for the company's future growth and market share. Furthermore, AVITA has a strong cash position and continues to improve its financials, making it a promising opportunity in the healthcare sector.
Bears say
AVITA Medical is a largely single product company with limited international expansion and over reliance on the US market. Despite reported increases in revenue in 2025, the company has faced disruption in reimbursement and operational stabilization, and future growth is largely execution-dependent. A lower operating cost base and new revenue guidance suggest potential for future growth, but a lack of diversification and reliance on a single product remains a concern.
This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
RCEL Analyst Forecast & Price Prediction
Start investing in RCEL
Order type
Buy in
Order amount
Est. shares
0 shares